

Author Index Volume 20 (2011)

The issue number is given in front of the pagination

- Ajayi, B.B., see Jeremiah, Z.A. (3,4) 77–82
Atiegoba, A.I., see Jeremiah, Z.A. (3,4) 71–75
- Baars, J.W., see Tran, L. (1,2) 29–35
Baars, J.W., see Tran, L. (1,2) 37–40
Baars, J.W., see Tran, L. (1,2) 7–14
Baba, M.M., see Jeremiah, Z.A. (3,4) 77–82
Beijnen, J.H., see Tran, L. (1,2) 29–35
Beijnen, J.H., see Tran, L. (1,2) 37–40
Beijnen, J.H., see Tran, L. (1,2) 7–14
Boxhammer, R., see Giblin, P. (3,4) 83–94
- Choo-Kang, E., see Roye-Green, K. (1,2) 1–5
Cooksley-Decasper, S., see Hof, D. (1,2) 15–27
- DaCosta, V., see Roye-Green, K. (1,2) 1–5
de Boer, J.P., see Tran, L. (1,2) 37–40
Desai, S., see Giblin, P. (3,4) 83–94
Dinant, H.J., see Tran, L. (1,2) 29–35
Dinant, H.J., see Tran, L. (1,2) 7–14
- Everett, E., see Kaja, S. (3,4) 95–101
Ezimah, A.C.U., see Jeremiah, Z.A. (3,4) 77–82
- Fletcher, H., see Roye-Green, K. (1,2) 1–5
Frederick, J., see Roye-Green, K. (1,2) 1–5
- Giblin, P., R. Boxhammer, S. Desai, R. Kroe-Barrett, G. Hansen, J. Ksiazek, M. Panzenbeck, K. Ralph, R. Schwartz, C. Zimmitti, C. Pracht, S. Miller, J. Magram and T. Litzenburger, Fully human antibodies against the Protease-Activated Receptor-2 (PAR-2) with anti-inflammatory activity (3,4) 83–94
Gossage, J., see Kaja, S. (3,4) 95–101
- Hansen, G., see Giblin, P. (3,4) 83–94
Hilgenberg, J.D., see Kaja, S. (3,4) 95–101
Hoefnagel, C.A., see Tran, L. (1,2) 37–40
- Hof, D., S. Cooksley-Decasper, S. Moergeli and A. von Eckardstein, Generation of novel recombinant antibodies against nitrotyrosine by antibody phage display (1,2) 15–27
Huitema, A.D.R., see Tran, L. (1,2) 29–35
Huitema, A.D.R., see Tran, L. (1,2) 37–40
Huitema, A.D.R., see Tran, L. (1,2) 7–14
- Idris, H., see Jeremiah, Z.A. (3,4) 77–82
- Jeremiah, Z.A., A.I. Atiegoba and O.Mgbere, Alloantibodies to human platelet glycoprotein antigens (HPA) and HLA class 1 in a cross section of Nigerian antenatal women (3,4) 71–75
- Jeremiah, Z.A., H. Idris, B.B. Ajayi, A.C.U. Ezimah, M.B. Malah and M.M. Baba, Isolated anti-HBc-IgM antibody among blood donors in the semi-arid region of Nigeria (3,4) 77–82
- Kaja, S., J.D. Hilgenberg, E. Everett, S.E. Olitsky, J. Gossage and P. Koulen, Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (AvastinTM) for topical delivery as a nasal spray in antihemorrhagic telangiectasia and related therapies (3,4) 95–101
Koulen, P., see Kaja, S. (3,4) 95–101
Kroe-Barrett, R., see Giblin, P. (3,4) 83–94
Ksiazek, J., see Giblin, P. (3,4) 83–94
- Litzenburger, T., see Giblin, P. (3,4) 83–94
- Magram, J., see Giblin, P. (3,4) 83–94
Malah, M.B., see Jeremiah, Z.A. (3,4) 77–82
Mgbere, O., see Jeremiah, Z.A. (3,4) 71–75
Miller, S., see Giblin, P. (3,4) 83–94
Moergeli, S., see Hof, D. (1,2) 15–27
Muller, S., see Tran, L. (1,2) 7–14

- Olitsky, S.E., see Kaja, S. (3,4) 95–101
- Panzenbeck, M., see Giblin, P. (3,4) 83–94
- Pracht, C., see Giblin, P. (3,4) 83–94
- Ralph, K., see Giblin, P. (3,4) 83–94
- Roye-Green, K., J. Frederick, G. Wharfe, E. Choo-Kang, V. DaCosta, H. Fletcher and M. Smikle, Antiphospholipid and other autoantibodies in a cohort of habitual aborters and healthy multiparous women in Jamaica (1,2) 1–5
- Schwartz, R., see Giblin, P. (3,4) 83–94
- Sinaasappel, M., see Tran, L. (1,2) 7–14
- Smikle, M., see Roye-Green, K. (1,2) 1–5
- Tran, L., A.D.R. Huitema, M.H. van Rijswijk, H.J. Dinant, J.W. Baars, J.H. Beijnen and W.V. Vogel, CD20 antigen imaging with ^{124}I -rituximab PET/CT in patients with rheumatoid arthritis (1,2) 29–35
- Tran, L., J.W. Baars, J.P. de Boer, C.A. Hoefnagel, J.H. Beijnen and A.D.R. Huitema, The pharmacokinetics of ^{131}I -rituximab in a patient with CD20 positive Non-Hodgkin Lymphoma: Evaluation of the effect of radioiodination on the biological properties of rituximab (1,2) 37–40
- Tran, L., W.V. Vogel, M. Sinaasappel, S. Muller, J.W. Baars, M. van Rijswijk, H.J. Dinant, J.H. Beijnen and A.D.R. Huitema, The pharmacokinetics of ^{124}I -rituximab in patients with rheumatoid arthritis (1,2) 7–14
- van Rijswijk, M., see Tran, L. (1,2) 7–14
- van Rijswijk, M.H., see Tran, L. (1,2) 29–35
- Vogel, W.V., see Tran, L. (1,2) 29–35
- Vogel, W.V., see Tran, L. (1,2) 7–14
- von Eckardstein, A., see Hof, D. (1,2) 15–27
- Wharfe, G., see Roye-Green, K. (1,2) 1–5
- Zimmitti, C., see Giblin, P. (3,4) 83–94